VIDEO: For patients with AML, ‘what are we going to add to our venetoclax regimen?’

ByAkriti Jain, MD

ByMarley V. Ghizzone

Fact checked byMindy Valcarcel, MS

SAN DIEGO — Akriti Jain, MD, spoke with Healio about combination therapy with venetoclax for acute myeloid leukemia presented at ASH Annual Meeting and Exposition.

“Another exciting part of our ASH meeting is, what are we going to add to our venetoclax [Venclexta; Genentech, AbbVie] regimen?” Jain, a leukemia and myeloid disorders physician at Cleveland Clinic, said.

Reference:

Gangat N, et al. Abstract 591. Presented at: ASH Annual Meeting and Exhibition; Dec. 9-12, 2023; San Diego.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Jain reports no relevant financial disclosures.

Take Homes in Leukemia

Read more

VIDEO: For patients with AML, ‘what are we going to add to our venetoclax regimen?’

Reference:

Related Content